Dr Mike Taussig - Founder and CEO
Mike Taussig was formerly head of the Protein Technology Group at the Babraham Institute, Cambridge UK. He has collaborated on the production of human antibodies from transgenic mice and codeveloped ribosome display technology, for selection of antibodies, and in situ protein arraying. He helped to establish two Institute spinout companies, Translocus Therapeutics and Discerna, and is a named co-inventor on patents for eukaryotic ribosome display and in situ protein arrays. Mike has wide experience of managing large EU and ESF networking and research projects, including three EU consortia aiming to establish European resources of affinity binding reagents for analysis of the human proteome, namely ProteomeBinders (2006-2010), AffinityProteome (2009-2012) and AFFINOMICS (2010-2015). He is a board member of the European Federation of Biotechnology and Editor in Chief of the EFB journal New Biotechnology (Elsevier). Mike is a Fellow of Selwyn College, Cambridge, where until recently he taught pathology. |
|
Cláudia Fonseca - COO
Cláudia Fonseca graduated in biological sciences from the University of Porto and subsequently was a research scientist at Ablynx, a leading biotechnology company developing single domain nanobodies, first in Porto and then in Ghent where her responsibilities were mainly in phage display of nanobodies. She joined the Babraham Institute as a research scientist in the Protein Technology Group in January 2014 and became a permanent staff member of Cambridge Protein Arrays Ltd. in June 2015. Her laboratory skills include different aspects of protein array systems, including design, preparation, sample processing and data analysis. In addition, she serves on the editorial team of the EFB journal New Biotechnology. |
|
